ALMIRALL SA
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Public, Subsidiary
- Established
- 1943-01-01
- Employees
- 1.9K
- Market Cap
- -
- Website
- http://www.almirall.com
Clinical Trials
44
Active:38
Completed:1
Trial Phases
3 Phases
Phase 1:14
Phase 3:1
Phase 4:2
Drug Approvals
114
CIMA_AEMPS:106
NMPA:5
EMA:3
Drug Approvals
Cinitapride Hydrogen Tartrate Tablets
- Product Name
- 希笛尼
- Approval Number
- 国药准字HJ20160477
- Approval Date
- Oct 29, 2024
NMPA
Cinitapride Hydrogen Tartrate Tablets
- Product Name
- 希笛尼
- Approval Number
- 国药准字J20171020
- Approval Date
- May 25, 2020
NMPA
Cinitapride Hydrogen Tartrate Tablets
- Product Name
- 希笛尼
- Approval Number
- H20170099
- Approval Date
- Feb 25, 2020
NMPA
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (82.4%)Phase 4
2 (11.8%)Phase 3
1 (5.9%)No trials found
News
FDA Approves Lilly's Ebglyss (lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis
The FDA has approved Ebglyss (lebrikizumab-lbkz) for adults and children 12+ with moderate-to-severe atopic dermatitis not controlled by topical treatments.
FDA Approves Lilly's Ebglyss (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
The FDA has approved Ebglyss (lebrikizumab) for adults and children 12 years and older with moderate-to-severe atopic dermatitis not well controlled by topical treatments.